These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 17064254

  • 21. Structure-activity relationship study on human urotensin II.
    Guerrini R, Camarda V, Marzola E, Arduin M, Calo G, Spagnol M, Rizzi A, Salvadori S, Regoli D.
    J Pept Sci; 2005 Feb; 11(2):85-90. PubMed ID: 15635628
    [Abstract] [Full Text] [Related]

  • 22. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ, Dong M, Ding XQ, Pinon DI, Miller LJ.
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [Abstract] [Full Text] [Related]

  • 23. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
    Lavecchia A, Cosconati S, Novellino E.
    J Med Chem; 2005 Apr 07; 48(7):2480-92. PubMed ID: 15801838
    [Abstract] [Full Text] [Related]

  • 24. Unraveling the active conformation of urotensin II.
    Carotenuto A, Grieco P, Campiglia P, Novellino E, Rovero P.
    J Med Chem; 2004 Mar 25; 47(7):1652-61. PubMed ID: 15027856
    [Abstract] [Full Text] [Related]

  • 25. A new ligand for the urotensin II receptor.
    Camarda V, Guerrini R, Kostenis E, Rizzi A, Calò G, Hattenberger A, Zucchini M, Salvadori S, Regoli D.
    Br J Pharmacol; 2002 Oct 25; 137(3):311-4. PubMed ID: 12237249
    [Abstract] [Full Text] [Related]

  • 26. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
    Grieco P, Carotenuto A, Campiglia P, Gomez-Monterrey I, Auriemma L, Sala M, Marcozzi C, d'Emmanuele di Villa Bianca R, Brancaccio D, Rovero P, Santicioli P, Meini S, Maggi CA, Novellino E.
    J Med Chem; 2009 Jul 09; 52(13):3927-40. PubMed ID: 19432421
    [Abstract] [Full Text] [Related]

  • 27. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
    Bhattacharya S, Hall SE, Vaidehi N.
    J Mol Biol; 2008 Oct 03; 382(2):539-55. PubMed ID: 18638482
    [Abstract] [Full Text] [Related]

  • 28. The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.
    Fillion D, Lemieux G, Basambombo LL, Lavigne P, Guillemette G, Leduc R, Escher E.
    J Med Chem; 2010 Mar 11; 53(5):2063-75. PubMed ID: 20146480
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
    Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt DB, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo' G, Camarda V, Aiyar NV, Douglas SA.
    Br J Pharmacol; 2006 May 11; 148(2):173-90. PubMed ID: 16547525
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T, Menon S, Sakmar TP.
    Biochemistry; 2008 Oct 21; 47(42):11013-23. PubMed ID: 18821775
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors.
    Dong M, Pinon DI, Asmann YW, Miller LJ.
    Mol Pharmacol; 2006 Jul 21; 70(1):206-13. PubMed ID: 16531505
    [Abstract] [Full Text] [Related]

  • 39. Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.
    Sainsily X, Cabana J, Holleran BJ, Escher E, Lavigne P, Leduc R.
    Biochem Pharmacol; 2014 Nov 15; 92(2):280-8. PubMed ID: 25175740
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.